Make an impact in the fight against heart disease by supporting me at the 💕 2026 Twin Cities Heart Walk! Will you consider making a donation today? #TCHeartWalk
https://t.co/3kZib0r4Sn
Take a #vacation w/o the stress of planning everything! My brother and SIL have >30 years of #travel agency exp between them, and they want to help plan your next #cruise or relaxing non-cruise vacation! Follow to learn about events & offers: https://t.co/s86c0emeGk
Heart disease remains the leading cause of death in the US and globally. Anteris is dedicated to raising awareness and funds for this crucial cause. Please consider supporting us in this endeavor!
https://t.co/qhSQTqNZ85 #StructuralHeart#TAVR
First in Europe #TAVR with ANTERIS DurAVR done at Karolinska. Complex anatomy: Valve-in-valve-in-valve. Impressive hemodynamic result with better flow now than in the original bioprosthesis with this novel balloon-expandable TAVI designed for maximal opening area.
Exciting news! Our ComASUR® Delivery System for our DurAVR® Transcatheter Heart Valve earned an Honorable Mention in the packaging category of Fast Company’s prestigious and highly competitive Innovation by Design Awards! This award is more than just recognition – it validates our commitment to forging new frontiers in cardiac care. Our unique packaging solution, developed in collaboration with IDEAZ, includes added functionality designed to enhance TAVR setup and streamline processes. The thermoform tray includes features such as a kickstand for easier insertion to the crimper and reservoirs for liquids used in the procedure.
This award is a testament to our dedication to daring to do things differently – because that’s what leads to groundbreaking scientific advancements. See how we’re making a difference: https://t.co/OqQ7gPKJ2u
#FCDesignAwards #innovation #packaging #TAVR #TAVI
DurAVR® INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.
ComASUR® Delivery System INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.
EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.
Anteris Technologies in Minneapolis, MN. Live and work in the happiest city in the United States! https://t.co/C4d7gDq727
Learn more about opportunities: https://t.co/hu0TNQiUDC
We are pleased to announce that the recording of our recent Annual General Meeting (AGM) is now available for viewing. This comprehensive session includes detailed discussions, strategic updates, and future plans that underscore the continued growth and innovation at Anteris Technologies.
Watch here: https://t.co/Oo7zkBnkKv
We invite all stakeholders, partners, and interested parties to watch this recording to stay informed about our latest developments and achievements. Your continued support and engagement are greatly appreciated.
#ProudtobeAnteris #AGM2024 #Innovation $AVR
Just wrapped up the AGM! Watch an exclusive post-AGM interview with our CEO, @CEOPaterson, as he discusses key highlights from the meeting, our latest achievements and future plans with @julesaly from @ausbiztv. Watch the interview here: https://t.co/uz5qkzd7uz
#asx $avr #duravr
In this expert interview, Dr. Vinayak Bapat interviews Dr. Anita Asgar regarding the challenges physicians face today with valve-in-valve (ViV) patients and the potential utility of DurAVR™ for ViV procedures through case-based discussion. Watch here ➡ https://t.co/aNQgs54MSw
First look at results from the DurAVR™ THV US EFS study! ➡️ https://t.co/VJDIYaJ1mt
Yesterday @AzeemLatib presented discharge data from the 15-patient #TAVR study. We’re extremely excited about the hemodynamic performance and potential patient impact!
#TCT2023#TAVI#innovation
Standing room only! At #TCT2023, @chrismeduri presented the latest data from the DurAVR™ THV FIH Study. Remarkable hemodynamic results are holding steady at 6 months and 1 year post-op! More info: https://t.co/qIicm0M8o2
#TAVR#TAVI#clinicaltrial#innovation